We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+0.65%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$73.9B
AUM Growth
-$2.32B
(-3%)
Cap. Flow
-$2.03B
Cap. Flow
% of AUM
-2.75%
Top 10 Holdings %
Top 10 Hldgs %
22.54%
Holding
3,088
New
92
Increased
1,359
Reduced
1,564
Closed
46
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Moderna
MRNA
|
+$60.7M |
| 2 |
Analog Devices
ADI
|
+$46.1M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$37.3M |
| 4 |
Match Group
MTCH
|
+$28.2M |
| 5 |
GXO Logistics
GXO
|
+$19.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$89.3M |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$78.9M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$77.4M |
| 4 |
Apple
AAPL
|
+$77M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$70.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.91% |
| 2 | Financials | 14.2% |
| 3 | Healthcare | 13.07% |
| 4 | Consumer Discretionary | 12.09% |
| 5 | Communication Services | 9.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NOTV
2826
DELISTED
Inotiv
NOTV
| $257K | ﹤0.01% |
+8,800
| New | +$256K |
|
2827
Red River Bancshares
RRBI
$659M
| $257K | ﹤0.01% |
5,152
+143
| +3% | +$7.22K |
|
|
PRTK
2828
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $257K | ﹤0.01% |
52,886
+2,150
| +4% | +$11.8K |
|
|
ATHX
2829
DELISTED
Athersys, Inc. Common Stock
ATHX
| $256K | ﹤0.01% |
7,709
+510
| +7% | +$19.4K |
|
2830
INNOVATE Corp
VATE
$165M
| $255K | ﹤0.01% |
6,219
+224
| +4% | +$8.37K |
|
2831
The Honest Company
HNST
$586M
| $254K | ﹤0.01% |
24,450
+1,027
| +4% | +$12.5K |
|
2832
Alta Equipment Group
ALTG
$245M
| $252K | ﹤0.01% |
18,343
+785
| +4% | +$10.3K |
|
2833
Cytek Biosciences
CTKB
$546M
| $252K | ﹤0.01% |
+11,761
| New | +$277K |
|
2834
Donegal Group Class A
DGICA
$714M
| $251K | ﹤0.01% |
17,348
+914
| +6% | +$13.8K |
|
2835
Aveanna Healthcare
AVAH
$2.07B
| $250K | ﹤0.01% |
31,199
+2,090
| +7% | +$20.3K |
|
2836
Lyell Immunopharma
LYEL
$360M
| $250K | ﹤0.01% |
+844
| New | +$253K |
|
|
PAMT
2837
PAMT Corp
PAMT
$297M
| $250K | ﹤0.01% |
+11,128
| New | +$191K |
|
|
AMPE
2838
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
| $249K | ﹤0.01% |
500
+30
| +6% | +$13.9K |
|
2839
Heritage Insurance Holdings
HRTG
$991M
| $247K | ﹤0.01% |
36,305
+758
| +2% | +$5.46K |
|
|
VEI
2840
DELISTED
Vine Energy Inc.
VEI
| $247K | ﹤0.01% |
15,020
+1,588
| +12% | +$23.8K |
|
2841
Smith Micro Software
SMSI
$16.2M
| $245K | ﹤0.01% |
1,264
+57
| +5% | +$11.5K |
|
2842
Global Water Resources
GWRS
$219M
| $242K | ﹤0.01% |
12,936
+575
| +5% | +$10.7K |
|
2843
Vor Biopharma
VOR
$1.28B
| $242K | ﹤0.01% |
770
+193
| +33% | +$57.4K |
|
2844
Applied Optoelectronics
AAOI
$11.5B
| $241K | ﹤0.01% |
33,543
-11,128
| -25% | -$82.1K |
|
2845
Janux Therapeutics
JANX
$967M
| $240K | ﹤0.01% |
+11,110
| New | +$320K |
|
2846
iShares S&P 100 ETF
OEF
$20.6B
| $239K | ﹤0.01% |
+1,209
| New | +$246K |
|
2847
Beam Global
BEEM
$25.3M
| $238K | ﹤0.01% |
8,713
+554
| +7% | +$16.5K |
|
|
WEBR
2848
DELISTED
Weber Inc.
WEBR
| $234K | ﹤0.01% |
+13,329
| New | +$214K |
|
2849
ClearPoint Neuro
CLPT
$433M
| $233K | ﹤0.01% |
13,153
+1,249
| +10% | +$23.4K |
|
2850
Evolus
EOLS
$501M
| $231K | ﹤0.01% |
30,348
+1,397
| +5% | +$14.4K |
|
Similar funds
VAM
RhumbLine Advisers's Q3 2021 Portfolio in Review
As of Q3 2021, RhumbLine Advisers held 3,088 positions worth $73.9B, down 3% from $76.2B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Trading was light in Q3 2021: portfolio turnover was 4.5%. RhumbLine Advisers opened 92 new positions and exited 46, leaving the 3,088-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 23% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q3 2021 buy was GXO Logistics: 250,722 shares worth $19.7M.
- RhumbLine Advisers added most to Moderna in Q3 2021, an estimated $60.7M increase.
- RhumbLine Advisers's biggest Q3 2021 reduction was Microsoft, cutting an estimated $89.3M.
- RhumbLine Advisers fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $77.4M.
- RhumbLine Advisers's ten largest holdings make up 23% of its $73.9B portfolio in Q3 2021.
- RhumbLine Advisers opened 92 new positions and closed 46 in Q3 2021.
- RhumbLine Advisers's portfolio value fell 3% quarter-over-quarter to $73.9B.
Based on RhumbLine Advisers's 13F filing for Q3 2021, filed 12 Nov 2021.